FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2904204913> ?p ?o ?g. }

• W2904204913 endingPage "3496" @default.
• W2904204913 startingPage "3496" @default.
• W2904204913 abstract "Abstract Introduction: BPX-501 is an allogeneic product consisting of T cells modified to express the inducible caspase-9 (iC9) safety switch, which can provide virus and tumor-specific immunity following stem cell transplant. In instances of graft-versus-host disease (GvHD), activation of iC9 with rimiducid leads to rapid killing of alloreactive T cells and resolution of GvHD. However, gene-modified T cells re-expand in the host. Here we evaluate the relationship between transgene expression and sensitivity to rimiducid to understand differential apoptosis in patients treated with allogeneic, iC9-modified T cells. Methods: The safety switch system consists of a bicistronic vector encoding a mutated FKBP12 binding protein linked to caspase-9 and truncated CD19 (ΔCD19) to allow selection of gene-modified T cells (SFG-iC9-ΔCD19). Exposure to rimiducid dimerizes iC9 resulting in apoptosis of gene-modified T cells. To evaluate the effect of transgene expression levels to the sensitivity of rimiducid-induced apoptosis, BPX-501 T cells were sorted into 3 equal populations based on the intensity of CD19 staining (CD19high, CD19med and CD19low). Phenotyping and functional assays (i.e., apoptosis) were performed by flow cytometry, qPCR and Western blot before and after T cell reactivation using anti-CD3/anti-CD28 antibodies. In vivo studies were performed by i.v. injection of control or gene-modified T cells co-expressing luciferase into NSG mice, followed by i.p. injection of a titrated dose of rimiducid (0.001 to 1 mg/kg), control drug (temsirolimus; 1 mg/kg) or vehicle. Bioluminescent imaging and flow cytometry were subsequently performed to assess in vivo depletion following iC9 activation. Results: Purity of BPX-501 cells after transduction and CD19 selection was 95%. Sorting BPX-501 cells based on CD19 mean fluorescence intensity (MFI) resulted in a CD19 MFI of 73, 46 and 22 for CD19 high, medium and low sorted populations, respectively. There was no significant difference in the percentage of CD8 and CD4 compartments among these cells, however, iC9-ΔCD19low expressing cells contained less terminal effector memory cells and more naïve-like cells than iC9-ΔCD19high (28±6% vs 39±8% (TEMRA), and 57±9% vs 42±12% (Naïve), respectively, P<0.05). In a 4-hour apoptosis assay, the killing efficiency was significantly diminished in iC9-ΔCD19low compared to unsorted or iC9-ΔCD19high cells (P<0.05, P<0.001, respectively). iC9-ΔCD19low cells also expressed less caspase-9 protein as measured by Western blot correlating to decreased rimiducid sensitivity. Animal studies showed a dose dependent decrease in the MFI of CD19 even in mice treated with 0.001 mg/kg of rimiducid demonstrating preferential killing of iC9-ΔCD19high T cells, and sparing of iC9-ΔCD19low T cells. However, because iC9-ΔCD19 transgene expression is regulated by the retroviral LTR promoter and sensitive to the activation state of the T cell, we measured the activation status following TCR cross-linking using CD25, CD69 and PD-1 markers, and transgene levels using CD19. While unstimulated iC9-ΔCD19 showed differential killing based on transgene expression (86%, 76% and 50% for high, medium and low iC9-ΔCD19, respectively), reactivation increased transgene MFI and apoptosis in all fractions to over 90% when exposed to rimiducid, confirming the relationship of T cell activation with transgene expression. Summary: In vivo depletion of T cells with iC9 is dependent on the level of transgene expression, which is regulated by the activation state of the T cell. Highly activated alloreactive T cells express higher levels of iC9 which makes them more sensitive to rimiducid-induced apoptosis, and serves to selectively deplete GvHD-causing T cells while sparing T cells with other specificities. Disclosures Zhou: Bellicum Pharmaceuticals: Employment, Equity Ownership. Lu:Bellicum Pharmaceuticals: Employment, Equity Ownership. Sharp:Bellicum Pharmaceuticals: Employment, Equity Ownership. Harris:Bellicum Pharmaceuticals: Employment, Equity Ownership. Anumula:Bellicum Pharmaceuticals: Employment, Equity Ownership. Bayle:Bellicum Pharmaceuticals: Employment, Equity Ownership. Spencer:Bellicum Pharmaceuticals: Employment, Equity Ownership. Foster:Bellicum: Employment, Equity Ownership. Shaw:Bellicum Pharmaceuticals: Employment, Equity Ownership." @default.
• W2904204913 created "2018-12-22" @default.
• W2904204913 creator A5001523714 @default.
• W2904204913 creator A5003796355 @default.
• W2904204913 creator A5013044088 @default.
• W2904204913 creator A5029718122 @default.
• W2904204913 creator A5036326281 @default.
• W2904204913 creator A5042807642 @default.
• W2904204913 creator A5063335678 @default.
• W2904204913 creator A5073052023 @default.
• W2904204913 creator A5079896846 @default.
• W2904204913 date "2018-11-29" @default.
• W2904204913 modified "2023-09-27" @default.
• W2904204913 title "Differential Expression of Inducible Caspase-9 (iC9) in Allogeneic T Cells Allows Selective Depletion of Activated T Cells Following Exposure to Rimiducid and Permits In Vivo Allodepletion" @default.
• W2904204913 doi "https://doi.org/10.1182/blood-2018-99-119285" @default.
• W2904204913 hasPublicationYear "2018" @default.
• W2904204913 type Work @default.
• W2904204913 sameAs 2904204913 @default.
• W2904204913 citedByCount "0" @default.
• W2904204913 crossrefType "journal-article" @default.
• W2904204913 hasAuthorship W2904204913A5001523714 @default.
• W2904204913 hasAuthorship W2904204913A5003796355 @default.
• W2904204913 hasAuthorship W2904204913A5013044088 @default.
• W2904204913 hasAuthorship W2904204913A5029718122 @default.
• W2904204913 hasAuthorship W2904204913A5036326281 @default.
• W2904204913 hasAuthorship W2904204913A5042807642 @default.
• W2904204913 hasAuthorship W2904204913A5063335678 @default.
• W2904204913 hasAuthorship W2904204913A5073052023 @default.
• W2904204913 hasAuthorship W2904204913A5079896846 @default.
• W2904204913 hasConcept C148125776 @default.
• W2904204913 hasConcept C153911025 @default.
• W2904204913 hasConcept C154317977 @default.
• W2904204913 hasConcept C190283241 @default.
• W2904204913 hasConcept C202751555 @default.
• W2904204913 hasConcept C203014093 @default.
• W2904204913 hasConcept C207001950 @default.
• W2904204913 hasConcept C2776090121 @default.
• W2904204913 hasConcept C2778957590 @default.
• W2904204913 hasConcept C502942594 @default.
• W2904204913 hasConcept C54355233 @default.
• W2904204913 hasConcept C553184892 @default.
• W2904204913 hasConcept C55493867 @default.
• W2904204913 hasConcept C86803240 @default.
• W2904204913 hasConcept C8891405 @default.
• W2904204913 hasConcept C95444343 @default.
• W2904204913 hasConceptScore W2904204913C148125776 @default.
• W2904204913 hasConceptScore W2904204913C153911025 @default.
• W2904204913 hasConceptScore W2904204913C154317977 @default.
• W2904204913 hasConceptScore W2904204913C190283241 @default.
• W2904204913 hasConceptScore W2904204913C202751555 @default.
• W2904204913 hasConceptScore W2904204913C203014093 @default.
• W2904204913 hasConceptScore W2904204913C207001950 @default.
• W2904204913 hasConceptScore W2904204913C2776090121 @default.
• W2904204913 hasConceptScore W2904204913C2778957590 @default.
• W2904204913 hasConceptScore W2904204913C502942594 @default.
• W2904204913 hasConceptScore W2904204913C54355233 @default.
• W2904204913 hasConceptScore W2904204913C553184892 @default.
• W2904204913 hasConceptScore W2904204913C55493867 @default.
• W2904204913 hasConceptScore W2904204913C86803240 @default.
• W2904204913 hasConceptScore W2904204913C8891405 @default.
• W2904204913 hasConceptScore W2904204913C95444343 @default.
• W2904204913 hasIssue "Supplement 1" @default.
• W2904204913 hasLocation W29042049131 @default.
• W2904204913 hasOpenAccess W2904204913 @default.
• W2904204913 hasPrimaryLocation W29042049131 @default.
• W2904204913 hasRelatedWork W2152593596 @default.
• W2904204913 hasRelatedWork W2355843056 @default.
• W2904204913 hasRelatedWork W2359289223 @default.
• W2904204913 hasRelatedWork W2373412498 @default.
• W2904204913 hasRelatedWork W2374966914 @default.
• W2904204913 hasRelatedWork W2380700939 @default.
• W2904204913 hasRelatedWork W2382426014 @default.
• W2904204913 hasRelatedWork W2385215236 @default.
• W2904204913 hasRelatedWork W2403432132 @default.
• W2904204913 hasRelatedWork W2917719117 @default.
• W2904204913 hasVolume "132" @default.
• W2904204913 isParatext "false" @default.
• W2904204913 isRetracted "false" @default.
• W2904204913 magId "2904204913" @default.
• W2904204913 workType "article" @default.